Registered Nurse in West Burlington, IA Accepting Medicare

6 Registered Nurse nurses found. Showing 1 - 6

Vivian Anderson, Registered Nurse - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1221 S Gear Ave, West Burlington, IA 52655 Phone: 319-768-1000

Ji Min Jung, Registered Nurse Medicare: Medicare Enrolled Practice Location: 1221 S Gear Ave, West Burlington, IA 52655 Phone: 319-768-1000

Jennifer Shelton, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 1221 S Gear Ave, West Burlington, IA 52655 Phone: 319-768-1000

Ms. Charissa Sallie Elliott, FNP Registered Nurse Medicare: Medicare Enrolled Practice Location: 1706 W Agency Rd, West Burlington, IA 52655 Phone: 319-768-5858    Fax: 319-752-4653

Jennifer Lin Clark, ARNP Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 1201 W Agency Rd, West Burlington, IA 52655 Phone: 319-754-4242

Mrs. Whitney Amelia Hall, Registered Nurse - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1223 S Gear Ave Ste 109, West Burlington, IA 52655 Phone: 319-768-1820

News Archive

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

Pharmavite LLC establishes direct-to-consumer sales company

Pharmavite LLC, the manufacturer and marketer of Nature Made® vitamins, minerals, herbs and other supplements and SOYJOY® snack bars, today announced the establishment of Pharmavite Direct LLC. Pharmavite Direct LLC is an internet-based, direct-to-consumer sales and marketing company.

Researchers are one step closer to devising an approach to identify pancreatic cancer earlier

Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will live five years after their diagnosis.

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

Read more Medical News

› Verified 2 days ago